decision analysis program data version 3.5 (treeage software)
90
Structured Review
treeage software
decision analysis program data version 3.5
Decision Analysis Program Data Version 3.5, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/decision+analysis+program+data+3%2E5/data+3+5/pmc06887568-154-8-14
Average 90 stars, based on 1 article reviews
Decision Analysis Program Data Version 3.5, supplied by treeage software, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/decision+analysis+program+data+3%2E5/data+3+5/pmc06887568-154-8-14
Average 90 stars, based on 1 article reviews
decision analysis program data version 3.5 - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Software:Article Title: Cost-Effectiveness Analysis of Strategies for the Surgical Management of Grade 1 Endometrial Adenocarcinoma Article Snippet: METHODS: A cost-effectiveness analysis compared three strategies for the management of grade 1 endometrial cancer: 1) surgical staging in all patients (including hysterectomy and lymphadenectomy); 2) frozen section following hysterectomy with surgical staging based on the results of tumor grade and depth of myometrial invasion; and 3) hysterectomy without surgical staging (no staging).. Surgical probabilities and recurrence rates were estimated from published data.. Actual payer costs of surgery, radiation therapy, and chemotherapy were estimated for each strategy. Article Title: Lynch Syndrome Screening Strategies Among Newly Diagnosed Endometrial Cancer Patients Article Snippet: METHODS: A decision analysis compared four strategies to screen women with newly diagnosed endometrial cancer for Lynch syndrome: 1) Amsterdam criteria strategy, where full gene sequencing was performed for women who meet Amsterdam criteria; 2) Sequence-all strategy, where full gene sequencing was performed for all women with endometrial cancer; 3) Sequence aged younger than 60 years strategy, where full gene sequencing was performed for women aged younger than 60 years with endometrial cancer; and 4) immunohistochemistry/single gene strategy, where immunohistochemistry was performed for the DNA mismatch repair genes for all women after single gene sequencing for specific women lacking protein expression.. Prevalence rates, probabilities of immunohistochemistry staining loss, and gene mutation rates were calculated from published data.. Costs were estimated from Medicare reimbursement rates. |